Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | KHK | P50053 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23578562 | 0.86 | MAOB (0.58) | MAOBCYP1A2GPR183KDM4EALDH1A1 | |
| SCHEMBL14329769 | 0.86 | MAOB (0.58) | MAOBCYP1A2GPR183KDM4EALDH1A1 | |
| SCHEMBL23578563 | 0.86 | MAOB (0.58) | MAOBCYP1A2GPR183KDM4EALDH1A1 | |
| SCHEMBL30683539 | 0.81 | MAOB (0.51) | MAOBKHKKDM1AALDH1A1HPGD | |
| SCHEMBL10069269 | 0.81 | MAOB (0.51) | MAOBCYP1A2KHKKDM1AALDH1A1 | |
| SCHEMBL5213208 | 0.81 | MAOB (0.51) | MAOBKHKMAOA | |
| SCHEMBL6011027 | 0.81 | TYR (0.42) | MAOBCYP1A2KHKKDM1AKDM4E | |
| SCHEMBL6011041 | 0.81 | MAOB (0.51) | MAOBKHKKDM1AALDH1A1HPGD | |
| SCHEMBL818902 | 0.81 | KDM1A (0.51) | MAOBKHKKDM1AALDH1A1MAOA | |
| SCHEMBL20015683 | 0.81 | KDM1A (0.51) | MAOBKHKKDM1AALDH1A1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018055096-A1 | DISUBTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES AS INHIBITORS OF MONOAMINE OXIDASE B FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF LJUBLJANA (SI) | 2018-03-29 | — | — | WO | disclosed |
| EP-1785415-B1 | PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1785415-A1 | PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | TRPV1, TRPA1, CACNA1D | MAOB 3198/4885CYP1A2 2337/4885KHK 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.